Glytec Receives FDA Breakthrough Device Designation for Glucommander Pediatrics, an Insulin Management Technology for Hospitalized Newborns and Infants

The designation covers hospitalized newborns and infants from birth to less than 2 years of age, a population for which no insulin dosing recommendation software has been FDA-cleared